1. 行政院衛生署統計資料網公告 http://www.doh.gov.tw/statistic/index.htm
2. Chen CY, Chen YC,Tang JL, Yao M, Huang SY, Tsai W, Chen YC, Shen MC, Wang CH, Tein HF.
Hepatosplenic fungal infection in patients with acute leukemia in Taiwan: incidence, treatment, and prognosis. Ann Hematol. 82:93-97, 2003.
3. Tsiftsoglou AS, Pappas IS, Vizirianakis IS. Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther. 100:257-290, 2003.
4. Balduf M, Steinkraus V, Mensing H. Acute myeloid leukemia: ecchymoses as sole clinical symptom.
Cutis. 53:131-133, 1994.
5. Mendeleeva LP. Allogenic bone marrow transplantation in acute leukemias and chronic myeloid leukemia Ter Arkh. 75:89-94, 2003.
6. Kim JA. Targeted therapies for the treatment of cancer. Am J Surg. 186:264-268, 2003.
7. 陳博明. 急性骨髓性白血病化學治療最近的進展.
臨床醫學 43:310-313, 1999
8. Powell BL. Acute progranulocytic leukemia. Curr Opin Oncol. 13:8-13, 2001.9. Fang J, Chen SJ, Tong JH, Wang ZG, Chen GQ, Chen Z. Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy. Cancer Biol
Ther. 1:614-620, 2002.
10. Duprez E, Wagner K, Koch H, Tenen DG. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J. 22:5806-5816, 2003.
11. Boda D, Virag I. Early results of vinblastine therapy in childhood tumours. Ther Hung. 18:15-19, 1970.
12. Takeshita A. Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents. Japanese J Clin Hematol. 44:1133-1143, 2003.
13. Lin RJ, Egan DA, Evans RM. Molecular genetics of acute promyelocytic leukemia. Trends Genet.
15:179-184, 1999.
14. Malumbres M, Carnero A. Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res.
5:5-18, 2003.
15. Dash BC, El-Deiry WS. Cell cycle checkpoint control mechanisms that can be disrupted in cancer.
Methods Mol Biol. 280:99-161, 2004.
16. Brown G, Hughes PJ, Michell RH. Cell differentiation and proliferation--simultaneous but independent? Exp Cell Res. 291:282-288, 2003.
17. Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S. Molucular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39-85, 2004.
18. Murray AW. Recycling the cell cycle: cyclins revisited. Cell. 116:221-234, 2004.
19. Schonthal AH. Measuring cyclin-dependent kinase activity. Methods Mol Biol. 281:105-124, 2004.
20. Meijer L. Chemical inhibitors of cyclin dependent kinases. Trends Cell Biol. 6:393-98, 1996.
21. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res. 8:2168-2181, 2001.
22. Swanton C. Cell-cycle targeted therapies. Lancet Oncol. 5:27-36, 2004.
23. Morgan DO. Principles of CDK regulation. Nature. 9:131-134, 1995.
24. Shapiro GI, Edwards CD, Rollins BJ. The physiology of p16(INK4A)-mediated G1 proliferative arrest.
Cell Biochem Biophys. 2:189-197, 2000.
25. Fotedar R, Bendjennat M, Fotedar A. Functional analysis of CDK inhibitor p21WAF1. Methods Mol
Biol. 281:55-72, 2004.
26. Fotedar R, Bendjennat M, Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle
2:134-137, 2004.
27. Musgrove EA, Davison EA, Ormandy CJ. Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice. J Mammary Gland Biol Neoplasia.
1:55-66, 2004.
28. Assoian RK. Stopping and going with p27kip1. Dev Cell. 4:458-459, 2004.
29. Chang TS, Kim MJ, Ryoo K, Park J, Eom SJ, Shim J, Nakayama KI, Nakayama K, Tomita M, Takahashi K, Lee MJ, Choi EJ. p57KIP2 modulates stress-activated signaling by inhibiting c-Jun NH2-terminal kinase/stress-activated protein Kinase. J Biol Chem. 48:48092-48098, 2003.
30. Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol. 3:362-370, 2003.
31. King RW, PK Jackson, Kirschner MW. Mitosis in transition. Cell. 79:563-571, 1994.
32. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis.
Toxicology. 181-182:475-481, 2002.
33. Boulikas T. Control of DNA replication by protein phosphorylation. Anticancer Res. 14:2465-2472, 1994.
34. Yang J, Yu Y, Duerksen-Hughes PJ. Protein kinases and their involvement in the cellular responses to genotoxic stress. Mutat Res. 543:31–58, 2003.
35. Blagosklonny MV. Apoptosis, proliferation, differentiation: in search of the order. Semin Cancer Biol.
13: 97–105, 2003
36. Danial NN, Korsmeyer SJ. Cell Death: critical control points. Cell. 116:205–219, 2004.
37. Kerr JF, Winterford CM, Harmon BV. Apoptosis: Its significance in cancer and cancer therapy.
Cancer. 8:2013-2026, 1994.
38. Gold R, Schmied M, Rothe G, Zischler H, Breitschopf H, Wekerle H, Lassmann H. Detection of DNA fragmentation in apoptosis: application of in situ nick translation to cell culture systems and tissue sections. J Histochem Cytochem. 7:1023-1030, 1993.
39. Vaux DL, Korsmeyer SJ. Cell death in development. Cell. 96:245-254, 1999.
40. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969–976, 1994.
41. Muzio M, Chinnaiyan AM, Kischkel FC, O’Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death–inducing signaling complex.
Cell. 85:817–827, 1996.
42. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME.
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14:5579–5588, 1995.
43. Brenner C, Kroemer G. Apoptosis. Mitochondria–the death signal integrators. Science. 289:
1150–1151, 2000.
44. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 406:855–862, 2000.
45. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Datta P, Alnemri ES, Shi Y, Dataa P. Structural basis of caspase-7 inhibition by XIAP. Cell. 104:769–780, 2001.
46. Green DR. Kroemer G. The pathophysiology of mitochondrial cell death. Science. 305:626-629, 2004.
48. Kohler C, Orrenius S, Zhivotovsky B. Evaluation of caspase activity in apoptotic cells. J Immunol
Methods. 265:97-110, 2002.
49. Abraham MC, Shaham S. Death without caspases, caspases without death. Trends Cell Biol.
14:184-193,2004.
50. Shi Y. Caspase activation: revisiting the induced proximity model. Cell. 117:855-858, 2004.
51. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol
Immunol. 11:615-647, 2003.
52. Allen RT, Cluck MW, Agrawal DK. Mechanisms controlling cellular suicide: role of Bcl-2 and caspases. Cell Mol Life Sci. 5:427-445, 1998.
53. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:334–336, 1990.
54. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim
Biophys Acta. 1644:83–94, 2004.
55. Akhtara RS, Nessc JM, Rotha KA. Bcl-2 family regulation of neuronal development and neurodegeneration. Biochim Biophys Acta. 1644:189–203, 2004.
56. Droin NM, Green DR. Role of Bcl-2 family members in immunity and disease. Biochim Biophys Acta.
1644:179–188, 2004.
57. Bonnefoy-Berarda N, Aouacheriab A, Verscheldea C, Quemeneura L, Marcaisa A, Marvela J.
Control of proliferation by Bcl-2 family members. Biochim Biophys Acta. 1644:159–168, 2004.
58. Donovan M, Cotter TG. Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death. Biochim Biophys Acta. 1644:133–147, 2004.
59. Sprick MR, Walczak H. The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta. 1644:125–132, 2004.
60. Sorenson CM. Bcl-2 family members and disease. Biochim Biophys Acta. 1644:169–177, 2004.
61. Kirkin V, Joos S, Zo¨rnig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys
Acta. 1644:229–249, 2004.
62. Rapp UR, Rennefahrt U, Troppmair J. Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim Biophys Acta. 1644:149–158, 2004.
63. Sharpe JC, Arnoult D, Youle RJ. Control of mitochondrial permeability by Bcl-2 family members.
Biochim Biophys Acta. 1644:107–113, 2004.
64. Kim MR, Tilly JL. Current concepts in Bcl-2 family member regulation of female germ cell development and survival. Biochim Biophys Acta. 1644:205–210, 2004.
65. Schinzel A, Kaufmann T, Borner C. Bcl-2 family members: intracellular targeting, membrane- insertion, and changes in subcellular localization. Biochim Biophys Acta. 1644:95–105, 2004.
66. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:609–619, 1993.
67. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.
Mol Cell. 104:705–711, 2001.
68. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1322-1326, 1998.
69. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 22:2922-2933, 2001.
70. Jiang X, Wang X. Cytochrome c-mediated apoptosis. Annu Rev Biochem. 73:87-106, 2004.
71. Okuno S, Shimizu S, Ito T, Nomura M, Hamada E, Tsujimoto Y, Matsuda H. Bcl-2 prevents caspase-independent cell death. J Biol Chem. 51:34272-34277, 1998.
72. Tsujimoto Y, Shimizu S, Eguchi Y, Kamiike W, Matsuda H. Bcl-2 and Bcl-xL block apoptosis as well as necrosis: possible involvement of common mediators in apoptotic and necrotic signal transduction pathways. Leukemia. 3:380-382, 1997.
73. Smith KG, Light A, O'Reilly LA, Ang SM, Strasser A, Tarlinton D. Bcl-2 transgene expression inhibits apoptosis in the germinal center and reveals differences in the selection of memory B cells and bone marrow antibody-forming cells. J Exp Med. 3:475-484, 2000.
74. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther. 2:S134-9, 2003.
75. Giver CR, Wong R, Moore DH, Pallavicini MG. Persistence of aneuploid immature/primitive hemopoietic sub-populations in mice 8 months after benzene exposure in vivo. Mutat Res.
491:127-138, 2001.
76. Herzog RW, Arruda VR. Update on gene therapy for hereditary hematological disorders. Expert Rev
Cardiovasc Ther. 1:215-232, 2003.
77. Amsellem S, Pflumio F, Bardinet D, Izac B, Charneau P, Romeo PH, Dubart-Kupperschmitt A, Fichelson S. In vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4
78. Kivekas I, Tobin G, Thunberg U, Vilpo L, Sundstrom C, Rosenquist R, Vilpo J. In vivo drug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells.
Leuk Res. 27:337-341, 2003.
79. Glass B, Uharek L, Zeis M, Loeffler H, Mueller-Ruchholtz W, Gassmann W. Graft- versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol. 93:412-420, 1996.
80. He Q, Na X. The effects and mechanisms of a novel 2-aminosteroid on murine WEHI-3B leukemia cells in vitro and in vivo. Leuk Res. 25:455-61, 2001.
81. Dong S, Hughes RC. Macrophage surface glycoproteins binding to galectin-3 (Mac-2-antigen).
Glycoconj J. 14:267-274, 1997.
82. Chang CY, Kuo SC, Lin Y L, Wang JP, Huang LJ. Benzyloxybenzaldehyde analogues as novel adenylyl cyclase activators. Bioorg Med Chem Lett. 11:1971-1974, 2001.
83. Wang JP, Chang LC, Hsu MF, Huang LJ, Kuo SC. 2-Benzyloxybenzaldehyde inhibits formyl-methionyl-leucyl-phenylalanine stimulation of phospholipase D activation in rat neutrophils.
Biochim Biophys Acta. 1573:26– 32, 2002.
84. Wang JP, Chang LC, Lin YL, Hsu MF, Chang CY, Huang LJ, Kuo SC. Investigation of the cellular mechanism of inhibition of formyl-methionyl-leucyl-phenylalanine-induced superoxide anion generation in rat neutrophils by 2-benzyloxybenzaldehyde. Biochem Pharmacol. 65:1043-1051, 2003.
85. Wang JP, Chang LC, Kuan YH, Tsao LT, Huang LJ, Kuo SC. 2-Benzyloxybenzaldehyde inhibits formyl peptide-stimulated increase in intracellular Ca2+ in neutrophils mainly by blocking Ca2+ entry.
Naunyn Schmiedebergs Arch Pharmacol. 370:353-360, 2004.
86. Pan SL, Guh J H, Huang Y W, Chang Y L, Chang CY, Huang LJ, Kuo SC, Teng CM. Inhibition of Ras-mediated cell proliferation by benzyloxybenzaldehyde. J Biomed Sci. 9:622-630, 2002.
87. Lin CF, Yang JS, Chang CY, Kuo SC, Lee MR, Huang LJ. Synthesis and anticancer activity of benzyloxybenzaldehyde derivatives against HL-60 cells. Bioorg Med Chem., 2005 (in press)
88. Kim SH, Kang SN, Kim HJ, Kim TS. Potentiation of 1,25-dihydroxyvitamin D(3)-induced differentiation of human promyelocytic leukemia cells into monocytes by costunolide, a germacranolide sesquiterpene lactone. Biochem Pharmacol. 64:1233-1242, 2002.
89. Weissgarten J, Berman S, Modai D, Rosenberg R, Rapoport M, Cohen M, Averbukh Z. Zn metabolism affects apoptosis rate and proliferative responsiveness of PBMC from patients on chronic hemodialysis. Metabolism. 51:1392-1396, 2002.
90. Zucker RM, Elstein KH, Easterling RE, Massaro EJ. Flow cytometric comparison of the effects of trialkyltins on the murine erythroleukemic cell. Toxicology. 58:107-119, 1989.
91. Okuma Y, Kiguchi K, Koshitaka Y, Okamura A, Ishiwata I, Kondo H, Ishizuka B, Tadokoro M.
Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines. Hum Cell. 16:131-139, 2003.
92. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol
Methods. 139:271-279, 1991.
93. Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B, Roessner A. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol. 164:1233-1241, 2004.
94. Hogquist KA, Nett MA, Unanue ER, Chaplin DD. Interleukin 1 is processed and released during apoptosis. Proc Natl Acad Sci USA. 88:8485-8489, 1991.
95. Kalbacova M, Vrbacky M, Drahota Z, Melkova Z. Comparison of the effect of mitochondrial inhibitors on mitochondrial membrane potential in two different cell lines using flow cytometry and spectrofluorometry. Cytometry. 52:110-116, 2003.
96. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J. Human ICE/CED-3 protease nomenclature. Cell. 87:171, 1996.
97. Chan HC, Kuo SC, Liu SC, Liu CH, Hsu SL. 4-Fluoro-N-butyl-phenylacetamide: a synthetic phenylacetate derivative that upregulates Bcl-X(S), activates caspase cascade and induces apoptosis in human squamous lung cancer CH27 cells. Cancer Lett. 186:211-221, 2002.
98. Hirai K, Sugawara T, Chan PH, Basus VJ, James TL, Litt L. Cytochrome c associated apoptosis during ATP recovery after hypoxia in neonatal rat cerebrocortical slices. J Neurochem.
83:309-319, 2002.
99. Chomczynski P, Mackey K. Modification of the Tri Reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. Biotechniques. 19:924-945,1995.
100. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987.
101. Young DS, Pestaner LC, Gibberman V. Effects of drugs on clinical laboratory tests. Clin Chem.
21:1D-432D, 1975.
102. Chochi K, Ichikura T, Majima T, Kawabata T, Matsumoto A, Sugasawa H, Kawarabayashi N, Takayama E, Hiraide H, Seki S, Mochizuki H. The increase of CD57+ T cells in the peripheral
blood and their impaired immune functions in patients with advanced gastric cancer. Oncol Rep.
10:1443-1448, 2003.
103. Jäättelä M. Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol. 4:416-23, 2003.
104. Gimonet D, Landais E, Bobichon H, Coninx P, Liautaud-Roger F. Induction of apoptosis by bleomycin in p53-null HL-60 leukemia cells. Int J Oncol. 24:313-9, 2004.
105. Hendrikse AS, Hunter AJ, Keraan M, Blekkenhorst GH. Effects of low dose irradiation on TK6 and U937 cells: induction of p53 and its role in cell-cycle delay and the adaptive response. Int J Radiat
Biol. 76:11-21, 2000.
106. Mahdi T, Alcalay D, Cognard C, Tanzer J, Kitzis A. Rescue of K562 cells from MDM2-modulated p53-dependent apoptosis by growth factor-induced differentiation. Biol Cell. 90:615-27, 1998.
107. Chen RJ, Lee WS, Liang YC, Lin JK, Wang YJ, Lin CH, Hsieh JY, Chaing CC, Ho YS.
Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines.
Toxicol Appl Pharmacol. 169:132-41, 2000.
108. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C, Otterson GA. 5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem. 279:15161-6, 2004.
109. Usuda J, Inomata M, Fukumoto H, Iwamoto Y, Suzuki T, Kuh HJ, Fukuoka K, Kato H, Saijo N, Nishio K. Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562/TPA cells. Int J Oncol. 22:81-6, 2003.
110. Shiohara M, Akashi M, Gombart AF, Yang R, Koeffler HP. Tumor necrosis factor alpha:
posttranscriptional stabilization of WAF1 mRNA in p53-deficient human leukemic cells. J Cell